COVIDCOMETE-19NCT04430322
Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study
An observational study of COVID, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.
Trial summary
France and especially the region "Grand Est" have been damaged by the COVID-19 pandemic. This pandemic resulted in a reorganization of the hospitalization sectors. In order to better understand the disease, the investigators wish to carry out a descriptive analysis of hospitalized patient data. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- COVID
- How many people
- 1,045 participants
- Where
- 1 siteFrance
- Study dates
- 1 Mar 2020to 1 Jun 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patient hospitalized in COVID Unit at the Regional Hospital Center Metz-Thionville during the COVID-19 pandemic with a PCR positive or COVID confirmed with clinical evidence and CT scan.
Who may be able to join
- Patient hospitalized in COVID Unit at the Regional Hospital Center Metz-Thionville during the COVID 19 pandemic
- PCR positive or COVID confirmed with clinical evidence and CT scan
Who cannot join
- Patients not willing to participate via using their medical files
- Patient transferred after a brief stay in another hospital
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Coronavirus Disease 2019 (Covid-19) at the Regional Hospital Center Metz-Thionville: a Descriptive Study
France and especially the region "Grand Est" have been damaged by the COVID-19 pandemic. This pandemic resulted in a reorganization of the hospitalization sectors.
In order to better understand the disease, the investigators wish to carry out a descriptive analysis of hospitalized patient data. This study would notably allow us to identify some prognostic factors.
The main objective of this study is to identify individual factors that are associated with a poor prognosis (with ICU admission or death).
- Conditions
- COVID
What is being measured
The primary outcome is the main question the study is designed to answer.
ICU admission
Number of ICU admission during the hospitalization
Measured: Day 1
Secondary outcomes (19)
Hospitalization
The duration of the hospitalization
Measured: Day 1
Length of stay at the ICU
The duration of stay at the ICU
Measured: Day 1
Death
The occurrence of death during the stay
Measured: Day 1
CT scan result
Evocative CT scan result
Measured: Day 1
C reactive protein
C reactive protein value
Measured: Day 1
Blood Count
Blood Count value
Measured: Day 1
Sodium
Sodium value
Measured: Day 1
Urea
Urea value
Measured: Day 1
Troponine
Troponine value via biological data
Measured: Day 1
Liver function
Transaminases value
Measured: Day 1
Coagulation test
Quick test result
Measured: Day 1
Creatinine
creatinine value
Measured: day 1
Clearance
creatinine clearance value
Measured: day 1
Potassium
potassium value
Measured: day 1
Calcium
calcium value
Measured: day 1
Gamma-glutamyl transpeptidase
Gamma-glutamyl transpeptidase value
Measured: day 1
Bilirubine
Bilirubine value
Measured: day 1
Alcaline phosphatase
Alcaline phosphatase value
Measured: Day 1
Prothrombine
Prothrombine value
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2020
- Study start1 Mar 2020
- Primary completion1 Jun 2022
- Study completion1 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 1,045 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Régional Metz-Thionville
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04430322
- Sponsor's protocol ID
- 2020-02Obs-CHRMT
- Acronym
- COMETE-19
- Status last verified
- Aug 2022
- First submitted
- 11 Jun 2020
- Last updated
- 29 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Louis G, Dinot V, Belveyre T, Dirand O, Dunand P, Cadoz C, Gaci R, Gette S, Perez P, Goetz C, Picard Y, Mellati N. Comparison of fully-vaccinated and non/partially-vaccinated critically-ill COVID-19 patients in terms of disease severity: a retrospective observational study. BMC Infect Dis. 2025 Oct 31;25(1):1457. doi: 10.1186/s12879-025-11904-4.
PubMed 41174545
Study at a glance
From the registry record, last updated by the sponsor on 29 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Coronavirus Disease 2019 (Covid-19) at the Regional Hospital Center Metz-Thionville: a Descriptive Study
- ClinicalTrials.gov ID
- NCT04430322
- Acronym / sponsor ID
- COMETE-19 / 2020-02Obs-CHRMT
- Conditions
- COVID
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,045 participants (actual)
- Lead sponsor
- Centre Hospitalier Régional Metz-ThionvilleUniversity, hospital or other
- Study start
- 1 Mar 2020 (actual)
- Primary completion
- 1 Jun 2022 (actual)
- Study completion
- 1 Jun 2022 (actual)
- First posted
- 12 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
France and especially the region "Grand Est" have been damaged by the COVID-19 pandemic. This pandemic resulted in a reorganization of the hospitalization sectors.
In order to better understand the disease, the investigators wish to carry out a descriptive analysis of hospitalized patient data. This study would notably allow us to identify some prognostic factors.
The main objective of this study is to identify individual factors that are associated with a poor prognosis (with ICU admission or death).
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patient hospitalized in COVID Unit at the Regional Hospital Center Metz-Thionville during the COVID-19 pandemic with a PCR positive or COVID confirmed with clinical evidence and CT scan.
Key inclusion criteria (2 listed)
- Patient hospitalized in COVID Unit at the Regional Hospital Center Metz-Thionville during the COVID 19 pandemic
- PCR positive or COVID confirmed with clinical evidence and CT scan
Key exclusion criteria (2 listed)
- Patients not willing to participate via using their medical files
- Patient transferred after a brief stay in another hospital
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
ICU admission
Time frame: Day 1
Number of ICU admission during the hospitalization
19 secondary outcomes
Hospitalization
Time frame: Day 1
Length of stay at the ICU
Time frame: Day 1
Death
Time frame: Day 1
CT scan result
Time frame: Day 1
C reactive protein
Time frame: Day 1
Blood Count
Time frame: Day 1
Sodium
Time frame: Day 1
Urea
Time frame: Day 1
Troponine
Time frame: Day 1
Liver function
Time frame: Day 1
Coagulation test
Time frame: Day 1
Creatinine
Time frame: day 1
Clearance
Time frame: day 1
Potassium
Time frame: day 1
Calcium
Time frame: day 1
Gamma-glutamyl transpeptidase
Time frame: day 1
Bilirubine
Time frame: day 1
Alcaline phosphatase
Time frame: Day 1
Prothrombine
Time frame: Day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Aug 2023.
- Derived from this study: PubMed 41174545Louis G, Dinot V, Belveyre T, Dirand O, Dunand P, Cadoz C, Gaci R, Gette S, Perez P, Goetz C, Picard Y, Mellati N. Comparison of fully-vaccinated and non/partially-vaccinated critically-ill COVID-19 patients in terms of disease severity: a retrospective observational study. BMC Infect Dis. 2025 Oct 31;25(1):1457. doi: 10.1186/s12879-025-11904-4.
Related trials for COVID
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ICU admission (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04430322, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Aug 2023.